Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14047172 | 1.00 | LMNA (0.48) | LMNAHTR1AHTR7SLC6A2SLC6A4 | |
| SCHEMBL13778643 | 1.00 | LMNA (0.48) | LMNAHTR1AHTR7SLC6A2SLC6A4 | |
| SCHEMBL9444870 | 0.84 | PTPN5 (0.51) | LMNASLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL11490664 | 0.84 | SLC6A2 (0.46) | LMNAHTR1AHTR7SLC6A2SLC6A4 | |
| SCHEMBL18406260 | 0.82 | LMNA (0.44) | LMNASLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL11483225 | 0.82 | SLC6A4 (0.49) | LMNAHTR1AHTR7SLC6A2SLC6A4 | |
| SCHEMBL11486383 | 0.81 | SLC6A4 (0.45) | LMNAHTR1AHTR7SLC6A2SLC6A4 | |
| SCHEMBL8420289 | 0.81 | HTR1A (0.46) | LMNAHTR1AHTR7SLC6A2SLC6A4 | |
| SCHEMBL22612419 | 0.81 | HTR1A (0.46) | LMNAHTR1AHTR7SLC6A2SLC6A4 | |
| SCHEMBL3510683 | 0.81 | HTR1A (0.46) | LMNAHTR1AHTR7SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192206-A1 | MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS | VAN LOMMEN GUY ROSALIA EUGEEN | 2009-07-30 | — | — | US | disclosed |
| US-20090192206-A1 | MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS | VAN LOMMEN GUY ROSALIA EUGEEN | 2009-07-30 | — | — | US | disclosed |
| US-7511068-B2 | Mercaptoimidazoles as CCR2 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
| US-7511068-B2 | Mercaptoimidazoles as CCR2 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
| EP-0450995-B1 | New propanamines, their pharmacological properties and their therapeutical applications, notably as anti-diarrhoea agents | JOUVEINAL SA (FR) | 1994-06-08 | — | — | EP | disclosed |
| US-5236947-A | Side effect reduction | JOUVEINAL S.A. (FR) | 1993-08-17 | — | — | US | disclosed |
| US-5143938-A | PROPANAMINES, THEIR PHARMACOLOGICAL PROPERTIES AND THEIR APPLICATION FOR THERAPEUTIC IN PARTICULAR ANTIDIARRHEAL, PURPOSES | JOUVEINAL S.A. (FR) | 1992-09-01 | — | — | US | disclosed |
| EP-0450995-A1 | New propanamines, their pharmacological properties and their therapeutical applications, notably as anti-diarrhoea agents | JOUVEINAL S.A. (FR) | 1991-10-09 | — | — | EP | disclosed |
| EP-0018144-A1 | A process for the preparation of substituted 2-aminopyrazines | ELI LILLY AND COMPANY (US) | 1980-10-29 | — | — | EP | disclosed |
| EP-0017494-A2 | Hydroxyimino-substituted aminoacetonitrile intermediates and their preparation | ELI LILLY AND COMPANY (US) | 1980-10-15 | — | — | EP | disclosed |
| US-4211870-A | FROM AMINOACETONITRILE AND A PHENYL A-HALO OXIME | ELI LILLY AND COMPANY (US) | 1980-07-08 | — | — | US | disclosed |
| US-4199525-A | Hydroxyimino-substituted aminoacetonitriles | ELI LILLY AND COMPANY (US) | 1980-04-22 | — | — | US | disclosed |
| US-4185992-A | Imidazole derivatives | MAY & BAKER LIMITED (GB) | 1980-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192206-A1 | MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS | CCR2, CCR1, CXCR3 | LMNA 4664/4885HTR1A 213/4885HTR7 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.